Movatterモバイル変換


[0]ホーム

URL:


SG11201909710XA - Indole ahr inhibitors and uses thereof - Google Patents

Indole ahr inhibitors and uses thereof

Info

Publication number
SG11201909710XA
SG11201909710XASG11201909710XASG11201909710XASG 11201909710X ASG11201909710X ASG 11201909710XASG 11201909710X ASG11201909710X ASG 11201909710XASG 11201909710X ASG11201909710X ASG 11201909710XA
Authority
SG
Singapore
Prior art keywords
international
massachusetts
april
pct
publication
Prior art date
Application number
Inventor
Alfredo C Castro
Catherine Anne Evans
Original Assignee
Kyn Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyn TherapeuticsfiledCriticalKyn Therapeutics
Publication of SG11201909710XApublicationCriticalpatent/SG11201909710XA/en

Links

Classifications

Landscapes

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) omit VIII °nolo VIII (10) International Publication Number WO 2018/195397 A3 WIPO I PCT (51) International Patent Classification: A01N 63/00 (2006.01) A61K 31/44 (2006.01) A61K 31/40 (2006.01) (21) International Application Number: PCT/US2018/028532 (22) International Filing Date: 20 April 2018 (20.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/488,476 21 April 2017 (21.04.2017) US 62/592,542 30 November 2017 (30.11.2017) US 62/658,454 16 April 2018 (16.04.2018) US (71) Applicant: KYN THERAPEUTICS [US/US]; 400 Tech- nology Square, 10th Floor, Cambridge, Massachusetts 02139 (US). (72) Inventors: CASTRO, Alfredo C.; 14 Kelly Drive, Woburn, Massachusetts 01801 (US). EVANS, Catherine Anne; 83 Jaques Street, Somerville, Massachusetts 02145 (US). (74) Agent: REID, Andrea L.C. et al.; One International Place, 100 Oliver Street, 40th Floor, Boston, Massachusetts 02110-2605 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (88) Date of publication of the international search report: 13 December 2018 (13.12.2018) O (57) : The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using 0 the same. (54) Title: INDOLE AHR INHIBITORS AND USES THEREOF
SG11201909710X2017-04-212018-04-20Indole ahr inhibitors and uses thereofSG11201909710XA (en)

Applications Claiming Priority (4)

Application NumberPriority DateFiling DateTitle
US201762488476P2017-04-212017-04-21
US201762592542P2017-11-302017-11-30
US201862658454P2018-04-162018-04-16
PCT/US2018/028532WO2018195397A2 (en)2017-04-212018-04-20Indole ahr inhibitors and uses thereof

Publications (1)

Publication NumberPublication Date
SG11201909710XAtrue SG11201909710XA (en)2019-11-28

Family

ID=63856153

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG11201909710XSG11201909710XA (en)2017-04-212018-04-20Indole ahr inhibitors and uses thereof

Country Status (15)

CountryLink
US (5)US10570138B2 (en)
EP (1)EP3612030A4 (en)
JP (2)JP7232244B2 (en)
KR (1)KR102668371B1 (en)
CN (1)CN110831600B (en)
AU (1)AU2018256459B2 (en)
CA (1)CA3059939A1 (en)
CL (1)CL2019003015A1 (en)
CO (1)CO2019011584A2 (en)
IL (1)IL270025B2 (en)
MX (1)MX2019012431A (en)
SG (1)SG11201909710XA (en)
TW (1)TWI778050B (en)
WO (1)WO2018195397A2 (en)
ZA (1)ZA201906822B (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CR20190282A (en)2016-12-162019-08-21Janssen Pharmaceutica NvSmall molecule inhibitors of the jak family of kinases
JOP20190144A1 (en)2016-12-162019-06-16Janssen Pharmaceutica NvImidazopyrrolopyridine as inhibitors of the jak family of kinases
TW201841916A (en)*2017-04-122018-12-01美商麥珍塔治療學股份有限公司 Aromatic hydrocarbon receptor antagonists and uses thereof
SG11201909710XA (en)2017-04-212019-11-28Kyn TherapeuticsIndole ahr inhibitors and uses thereof
FR3066761B1 (en)*2017-05-232020-10-30Centre Nat Rech Scient NEW IONIC CHANNEL INHIBITORS
KR20200051646A (en)2017-08-172020-05-13이케나 온콜로지, 인코포레이티드 AHR inhibitors and uses thereof
WO2019156989A1 (en)*2018-02-062019-08-15Ideaya Biosciences, Inc.COMPOUNDS AND METHODS FOR THE MODULATION OF AhR
FI3749669T6 (en)2018-02-062024-11-13Ideaya Biosciences IncAhr modulators
TW202016110A (en)2018-06-152020-05-01比利時商健生藥品公司 Small molecule inhibitors of the JAK kinase family
US11932657B2 (en)*2018-09-072024-03-19Otsuka Pharmaceutical Co., Ltd.Heterocyclic compound
SG11202103796TA (en)*2018-10-162021-05-28Ikena Oncology IncIndole ahr inhibitors and uses thereof
WO2020081840A1 (en)*2018-10-172020-04-23Magenta Therapeutics Inc.Methods of treating cancer with aryl hydrocarbon receptor antagonists
EA202191507A1 (en)*2018-11-302021-08-20Селулэрити Инк. AROMATIC COMPOUNDS FOR USE TO ACTIVATE HEALTH STEM CELLS AND PROCESS CELLS
EP3887508A1 (en)*2018-11-302021-10-06Celularity Inc.Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
CN109813913B (en)*2019-01-312021-11-09中国医学科学院肿瘤医院Use of aromatic hydrocarbon receptor (AhR) for predicting immunotherapy effect
CA3128521A1 (en)*2019-02-272020-09-03Millennium Pharmaceuticals, Inc.Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
EP4003337A4 (en)*2019-07-302023-06-28Oregon State UniversityAryl hydrocarbon receptor activators
KR20220119537A (en)*2019-11-222022-08-29센다 바이오사이언시즈, 인크. Pyridopyrimidinone derivatives as AHR antagonists
ES3028099T3 (en)2019-11-262025-06-18Ikena Oncology IncPolymorphic carbazole derivatives and uses thereof
EP4065586A1 (en)*2019-11-262022-10-05F. Hoffmann-La Roche AG1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease
MX2022006312A (en)*2019-11-262022-06-22Ikena Oncology IncAhr inhibitors and uses thereof.
TW202146416A (en)2019-12-112021-12-16德商拜耳廠股份有限公司Pyrazolotriazines
KR20220125323A (en)2020-01-102022-09-14이케나 온콜로지, 인코포레이티드 AHR inhibitors and uses thereof
KR20220153595A (en)2020-02-262022-11-18재규어 테라퓨틱스 피티이 리미티드 Pyridopyrimidine derivatives useful for modulating AhR signaling
KR20230005844A (en)*2020-03-272023-01-10동아에스티 주식회사 Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators
US20240350492A1 (en)2020-07-102024-10-24Ting Therapeutics LlcMethods for the Prevention and Treatment of Hearing Loss
WO2022029063A1 (en)*2020-08-042022-02-10Bayer AktiengesellschaftPyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines
CN114369097B (en)*2020-10-152023-07-14山东轩竹医药科技有限公司Heteroaromatic AhR inhibitors
EP4236960A1 (en)2020-10-282023-09-06Ikena Oncology, Inc.Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
CN114644627B (en)*2020-12-182024-06-11山东轩竹医药科技有限公司AhR inhibitors and uses thereof
CN112656789A (en)*2020-12-312021-04-16中国科学院生态环境研究中心Application of FICZ in inhibiting tumor cell migration
CN114805361B (en)*2021-01-172024-02-20上海凌达生物医药有限公司Amino substituted aromatic heterocyclic pyrazole compound, preparation method and application
CA3213134A1 (en)2021-03-112022-09-15Janssen Pharmaceutica NvLorpucitinib for use in the treatment of jak mediated disorders
WO2023020512A1 (en)*2021-08-162023-02-23成都奥睿药业有限公司Substituted pyridine analogue, preparation method therefor, and use thereof as ahr modulator
WO2023033742A1 (en)*2021-09-022023-03-09Jaguahr Therapeutics Pte LtdCompounds useful in modulation of ahr signalling
WO2023033741A1 (en)*2021-09-022023-03-09Jaguahr Therapeutics Pte LtdCompounds useful in modulation of ahr signalling
EP4396191A1 (en)*2021-09-022024-07-10Jaguahr Therapeutics Pte LtdCompounds useful in modulation of ahr signalling
CN115093400B (en)*2021-09-182023-09-05北京华森英诺生物科技有限公司AhR inhibitor, application and preparation method thereof
WO2023060227A1 (en)2021-10-072023-04-13Ikena Oncology, Inc.Tead inhibitors and uses thereof
CN115925684B (en)*2021-12-032025-02-28徐诺药业(南京)有限公司 A pyrimidine derivative and its preparation method and application
JP2025502240A (en)2022-01-112025-01-24ドイッチェス・クレープスフォルシュングスツェントルム Bicyclic triazine derivatives for the treatment of cancer - Patents.com
CN117624168A (en)*2022-08-192024-03-01德明药泰生物技术(深圳)有限公司 Fused ring heterocyclic compounds and their preparation methods and applications
CN115850329A (en)*2022-09-162023-03-28东莞市均成高新材料有限公司 Cyclic teraryl phosphines, their preparation and use
KR20250073623A (en)2022-10-032025-05-27재규어 테라퓨틱스 피티이 리미티드 Compounds useful for modulating AhR signaling
CN115804776A (en)*2022-12-162023-03-17国纳之星(上海)纳米科技发展有限公司Application of aromatic hydrocarbon receptor inhibitor and 5-fluorouracil in combination in tumor treatment and inhibition drugs
CN116482278B (en)*2023-05-062024-02-09广州清瑞生物科技有限责任公司Preparation method of reference substance for detecting acyclovir
TW202510855A (en)*2023-08-182025-03-16美商英塞特公司Bicyclic heterocycles as mrgprx2 antagonists
EP4512806A1 (en)2023-08-252025-02-26Mablink BioscienceMolecular glue degraders and uses thereof
EP4512427A1 (en)2023-08-252025-02-26Mablink BioscienceAntibody-drug conjugates based on molecular glue degraders and uses thereof
CN117229284B (en)*2023-11-102024-02-06上海泽德曼医药科技有限公司Tricyclic fused heterocyclic compound, preparation method and application thereof in medicine
WO2025114771A1 (en)2023-11-292025-06-05Latvian Institute Of Organic SynthesisA new class of aryl hydrocarbon receptor antagonists and their optimisation

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5721356A (en)1989-09-151998-02-24Gensia, Inc.Orally active adenosine kinase inhibitors
EA006626B1 (en)*1996-07-242006-02-24Дюпон Фармасьютикалз КомпаниAzolo pyrimidines, pharmaceutical composition and method for treatment
US5962473A (en)1996-08-161999-10-05Eli Lilly And CompanyMethods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
US6608053B2 (en)2000-04-272003-08-19Yamanouchi Pharmaceutical Co., Ltd.Fused heteroaryl derivatives
SK8192003A3 (en)2000-12-192003-10-07Merck Patent GmbhPharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives
US20040235877A1 (en)*2001-09-142004-11-25Natsuki IshizukaNovel use of tricyclic compound
JP2006501260A (en)*2002-09-042006-01-12シェーリング コーポレイション Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
KR20050052500A (en)*2002-09-192005-06-02쉐링 코포레이션Imidazopyridines as cyclin dependent kinase inhibitors
AU2004230928B2 (en)2003-04-092010-12-02Exelixis, Inc.Tie-2 modulators and methods of use
AR047969A1 (en)2004-02-252006-03-15Schering Corp PIRAZOLOTRIAZINAS AS QUINASA INHIBITORS
TWI309240B (en)2004-09-172009-05-01Hoffmann La RocheAnti-ox40l antibodies
AU2005323311A1 (en)2004-11-232006-07-13Venkateswara Rao BatchuNovel bicyclic heterocyclic compounds, process for their preparation and compositions containing them
PT2343320T (en)2005-03-252018-01-23Gitr IncAnti-gitr antibodies and uses thereof
EP1879573B1 (en)2005-05-102012-12-19Incyte CorporationModulators of indoleamine 2,3-dioxygenase and methods of using the same
CA3201163A1 (en)2005-07-012007-01-11E. R. Squibb & Sons, L.L.C.Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US20070078136A1 (en)*2005-09-222007-04-05Bristol-Myers Squibb CompanyFused heterocyclic compounds useful as kinase modulators
CA2634198C (en)2005-12-202014-06-03Incyte CorporationN-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
ES2444574T3 (en)2006-09-192014-02-25Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indolamine 2,3-dioxygenase
CL2007002650A1 (en)2006-09-192008-02-08Incyte Corp COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS.
AU2007316417B2 (en)*2006-11-062013-08-22Tolero Pharmaceuticals, Inc.Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
EP1987839A1 (en)2007-04-302008-11-05I.N.S.E.R.M. Institut National de la Sante et de la Recherche MedicaleCytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2009009116A2 (en)2007-07-122009-01-15Tolerx, Inc.Combination therapies employing gitr binding molecules
EP2044949A1 (en)2007-10-052009-04-08ImmutepUse of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CN101932325B (en)2007-11-302014-05-28新联基因公司Ido inhibitors
EP2229390B1 (en)*2007-12-142014-04-09F. Hoffmann-La Roche AGNovel imidazoý1,2-a¨pyridine and imidazoý1,2-b¨pyridazine derivatives
KR20110013421A (en)2008-05-292011-02-09생-고뱅 생트레 드 레체르체 에 데투드 유로삐엔 Aluminum titanate-containing porous structure
AR072999A1 (en)2008-08-112010-10-06Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
PE20100362A1 (en)2008-10-302010-05-27Irm Llc PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS
PT4209510T (en)2008-12-092024-04-02Hoffmann La RocheAnti-pd-l1 antibodies and their use to enhance t-cell function
ES2788869T3 (en)2009-09-032020-10-23Merck Sharp & Dohme Anti-GITR antibodies
EP2493862B1 (en)2009-10-282016-10-05Newlink Genetics CorporationImidazole derivatives as ido inhibitors
JP5802676B2 (en)2009-12-042015-10-28センワ バイオサイエンシズ インコーポレイテッド Pyrazolopyrimidines and related heterocyclic compounds as CK2 inhibitors
RU2565541C2 (en)2009-12-102015-10-20Ф.Хоффманн-Ля Рош АгAntibodies primarily binding to extracellular domain 4 of human csf-1r, and using them
BR122016002916B8 (en)2010-03-042021-05-25Macrogenics Inc diabody, nucleic acid molecule, pharmaceutical composition and uses of diabody
KR101647871B1 (en)2010-03-052016-08-11에프. 호프만-라 로슈 아게Antibodies against human csf-1r and uses thereof
BR112012020372A8 (en)2010-03-052018-01-02Hoffmann La Roche human csf-1r binding antibody, pharmaceutical composition, nucleic acid, expression vectors, host cell and method for producing a recombinant antibody
SG10201911345WA (en)2010-05-042020-01-30Five Prime Therapeutics IncAntibodies that bind csf1r
PE20131465A1 (en)2010-09-092014-01-04Pfizer UNION MOLECULES A 4-1 BB
US8957077B2 (en)*2010-09-302015-02-17Merck Sharp & Dohme Corp.Pyrazolopyrimidine PDE 10 inhibitors
PH12013501201A1 (en)2010-12-092013-07-29Univ PennsylvaniaUse of chimeric antigen receptor-modified t cells to treat cancer
GB201103837D0 (en)2011-03-072011-04-20Oxagen LtdAmorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
NO2694640T3 (en)2011-04-152018-03-17
KR101970025B1 (en)2011-04-202019-04-17메디뮨 엘엘씨Antibodies and other molecules that bind b7-h1 and pd-1
SG194549A1 (en)2011-04-212013-12-30Origenis GmbhPyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
AU2012344260B2 (en)2011-11-282017-09-07Merck Patent GmbhAnti-PD-L1 antibodies and uses thereof
AU2012347534B2 (en)*2011-12-082018-01-25Fred Hutchinson Cancer Research CenterCompositions and methods for enhanced generation of hematopoietic stem/progenitor cells
US10023643B2 (en)2011-12-152018-07-17Hoffmann-La Roche Inc.Antibodies against human CSF-1R and uses thereof
EP2812355A4 (en)2012-02-062016-03-02Hoffmann La Roche COMPOSITIONS AND METHODS OF USING CSF1R INHIBITORS
AR090263A1 (en)2012-03-082014-10-29Hoffmann La Roche COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME
AR090650A1 (en)2012-04-122014-11-26Alcon Res Ltd TREATMENT FOR INFLAMMATORY RESPONSES INDUCED BY EYE MICROBES
HK1208233A1 (en)2012-05-112016-02-26戊瑞治疗有限公司Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
UY34887A (en)2012-07-022013-12-31Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
US20140079699A1 (en)2012-08-312014-03-20Five Prime Therapeutics, Inc.Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2014060112A1 (en)*2012-10-192014-04-24Origenis GmbhPyrazolo[4,3-d]pyrimidines as kinase inhibitors
WO2014138485A1 (en)*2013-03-082014-09-12Irm LlcEx vivo production of platelets from hematopoietic stem cells and the product thereof
WO2017004405A1 (en)2015-07-012017-01-05Northwestern UniversitySubstituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity
US20180072741A1 (en)2016-09-092018-03-15Incyte CorporationPyrazolopyrimidine compounds and uses thereof
TW201841916A (en)2017-04-122018-12-01美商麥珍塔治療學股份有限公司 Aromatic hydrocarbon receptor antagonists and uses thereof
SG11201909710XA (en)2017-04-212019-11-28Kyn TherapeuticsIndole ahr inhibitors and uses thereof
SG11202103796TA (en)2018-10-162021-05-28Ikena Oncology IncIndole ahr inhibitors and uses thereof
ES3028099T3 (en)2019-11-262025-06-18Ikena Oncology IncPolymorphic carbazole derivatives and uses thereof
MX2022006312A (en)2019-11-262022-06-22Ikena Oncology IncAhr inhibitors and uses thereof.
KR20220125323A (en)2020-01-102022-09-14이케나 온콜로지, 인코포레이티드 AHR inhibitors and uses thereof
EP4236960A1 (en)2020-10-282023-09-06Ikena Oncology, Inc.Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine

Also Published As

Publication numberPublication date
US10570138B2 (en)2020-02-25
IL270025A (en)2019-12-31
EP3612030A4 (en)2021-04-28
EP3612030A2 (en)2020-02-26
CN110831600A (en)2020-02-21
US20230028336A1 (en)2023-01-26
US20200331917A1 (en)2020-10-22
US20250122205A1 (en)2025-04-17
BR112019021992A2 (en)2020-06-09
JP2020517734A (en)2020-06-18
WO2018195397A2 (en)2018-10-25
IL270025B1 (en)2023-01-01
JP2022116319A (en)2022-08-09
AU2018256459A1 (en)2019-11-07
CO2019011584A2 (en)2020-02-18
ZA201906822B (en)2024-06-26
JP7232244B2 (en)2023-03-08
WO2018195397A3 (en)2018-12-13
AU2018256459B2 (en)2023-12-07
US10689388B1 (en)2020-06-23
CA3059939A1 (en)2018-10-25
CN110831600B (en)2023-10-17
US11358969B2 (en)2022-06-14
MX2019012431A (en)2020-08-03
KR20190141722A (en)2019-12-24
TW201841917A (en)2018-12-01
KR102668371B1 (en)2024-05-28
US12077542B2 (en)2024-09-03
IL270025B2 (en)2023-05-01
US20180327411A1 (en)2018-11-15
CL2019003015A1 (en)2020-03-27
TWI778050B (en)2022-09-21

Similar Documents

PublicationPublication DateTitle
SG11201909710XA (en)Indole ahr inhibitors and uses thereof
SG11201806544XA (en)Compounds and methods of treating rna-mediated diseases
SG11201808799SA (en)Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
SG11201909949XA (en)Targeted immunotolerance
SG11201805300QA (en)Heterocyclic compounds as immunomodulators
SG11201908719QA (en)Biomarkers and car t cell therapies with enhanced efficacy
SG11201808990QA (en)Compositions for topical application of compounds
SG11201808682XA (en)Silicone atoms containing ivacaftor analogues
SG11201809344QA (en)Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201805709RA (en)Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201805449PA (en)Methods of making chimeric antigen receptor -expressing cells
SG11201806583XA (en)Compositions containing tucaresol or its analogs
SG11201811643TA (en)Compounds and methods for modulating rna function
SG11201808751SA (en)T cell receptors
SG11201805645QA (en)Lsd1 inhibitors
SG11201804901WA (en)Compounds for the treatment of cancer and inflammatory disease
SG11201907840RA (en)Fused imidazo-piperidine jak inhibitors
SG11201809499UA (en)Processes for preparing phosphorodiamidate morpholino oligomers
SG11201803920TA (en)Compounds and compositions useful for treating disorders related to ntrk
SG11201805149XA (en)Compositions comprising 15-hepe and methods of using the same
SG11201901251SA (en)Aminopyrimidines as alk inhibitors
SG11201908624SA (en)Aryl hydrocarbon receptor antagonists and uses thereof
SG11201900545TA (en)Pharmaceutical compounds
SG11201809497RA (en)Processes for preparing phosphorodiamidate morpholino oligomers
SG11201907364WA (en)Anti-tryptase antibodies, compositions thereof, and uses thereof

[8]ページ先頭

©2009-2025 Movatter.jp